545. Remdesivir And Obeldesivir Retain Potent Activity Against SARS-CoV-2 Omicron Variants

BACKGROUND: Remdesivir (RDV), a nucleotide analog prodrug that targets the viral RNA-dependent RNA polymerase Nsp12, is approved to treat COVID-19 in hospitalized and nonhospitalized patients. Obeldesivir (ODV), an oral mono-5’-isobutyryl ester prodrug that is metabolized into the same active tripho...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez, Lauren, Li, Jiani, Han, Dong, Martin, Ross, Moshiri, Jasmine, Peinovich, Nadine, Bilello, John P, Perry, Jason K, Hedskog, Charlotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679263/
http://dx.doi.org/10.1093/ofid/ofad500.614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679263/
http://dx.doi.org/10.1093/ofid/ofad500.614

Ejemplares similares